Targeting Shingosine-1-Phosphate (S1P) Receptors, patent summary 2010

Shingosine 1-Phopshate (S1P) is a bioactive sphingolipid metabolite generated from endogenous sphingosine through phosphorylation by specific kinases, named sphingosine kinases 1 and 2.

S1P acts as an agonist on a family of G protein-coupled receptors (GPCRs) with seven-transmembrane domain. Five sphingosine 1-phosphate receptors have been identified (S1P1 to S1P5, also known as endothelial differentiation genes (EDG) receptors, EDG1, EDG5, EDG3, EDG6 and EDG8 respectively).

S1P1, S1P4 and S1P5 receptors activate Gi but not Gq, whereas S1P2 and S1P3 receptors activate both Gi and Gq. The S1P3 receptor, but not the S1P1 receptor, responds to an agonist with an increase in intracellular calcium.

S1P has been demonstrated to induce many cellular effects, including those that result in platelet aggregation, cell proliferation, cell morphology, tumor cell invasion, endothelial cell and leukocyte chemotaxis, endothelial cell in vitro angiogenesis, and lymphocyte trafficking.

S1P receptors are therefore good targets for a wide variety of therapeutic applications such as tumor growth inhibition, vascular disease, and autoimmune diseases.

Company Patent number
ABBOTT LABORATORIES WO 2010093616
AKAAL PHARMA PTY LTD WO 2010042998
AKAAL PHARMA PTY LTD WO 2010043000
ALLERGAN, INC. WO 2010002820
ALLERGAN, INC. WO 2010019646
ALMIRALL, S.A. WO 2010043377
ALMIRALL, S.A. WO 2010081692
ARENA PHARMACEUTICALS, INC. WO 2010027431
ARENA PHARMACEUTICALS, INC. WO 2010011316
ASTELLAS PHARMA INC. WO 2010064707
BEIJING FUKA BIOLOGICAL SCIENCE & TECHNOLOGY, LTD WO 2010078711
BIOGEN IDEC MA INC. WO 2010051030
BRISTOL-MYERS SQUIBB COMPANY WO 2010085581
BRISTOL-MYERS SQUIBB COMPANY WO 2010085582
BRISTOL-MYERS SQUIBB COMPANY WO 2010085584
EXELIXIS, INC. WO 2010045580
GLAXO GROUP LIMITED WO 2010145203
GLAXO GROUP LIMITED WO 2010146105
GLAXO GROUP LIMITED WO 2010148649
GLAXO GROUP LIMITED WO 2010148650
LEXICON PHARMACEUTICALS, INC. WO 2010051349
MERCK SERONO S.A. WO 2010100142
NOVARTIS AG WO 2010010127

Site Search